---
title: A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941
nct_id: NCT01187186
overall_status: COMPLETED
phase: PHASE1
sponsor: Astellas Pharma Inc
study_type: INTERVENTIONAL
primary_condition: Liver Disease
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01187186.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01187186"
ct_last_update_post_date: 2010-10-07
last_seen_at: "2026-05-12T07:04:22.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941

**Official Title:** A Phase 1, Open-Label, Single-Dose Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941

**NCT ID:** [NCT01187186](https://clinicaltrials.gov/study/NCT01187186)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 16
- **Lead Sponsor:** Astellas Pharma Inc
- **Conditions:** Liver Disease
- **Start Date:** 2010-05
- **Completion Date:** 2010-08
- **CT.gov Last Update:** 2010-10-07

## Brief Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) and safety following oral administration of ASP1941 in subjects with moderate hepatic impairment and in subjects with normal hepatic function based on the Child-Pugh Classification (CPC).

## Detailed Description

Study drug will be orally administered on Day 1. Subjects will be admitted to the clinic until completion of clinic discharge procedures on Day 7 with an outpatient follow-up visit 6-9 days after clinic discharge.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 69 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Subjects with Moderate Hepatic Impairment

  * Agrees to practice highly effective birth control until 7 days post dose. If female, two years post-menopausal, surgically sterile, and not pregnant or lactating
  * Weights at least 45 kg
  * Body mass index between 18 and 34 kg/m2
  * Meets criteria for moderate hepatic impairment defined by Child-Pugh method
* Subjects with Normal Hepatic Function

  * Agrees to practice highly effective birth control until 7 days post dose. If female, two years post-menopausal, surgically sterile, and not pregnant or lactating
  * Weights at least 45 kg
  * Body mass index between 18 and 34 kg/m2
  * Must have normal hepatic function defined by Child-Pugh method

Exclusion Criteria:

* Subjects with Moderate Hepatic Impairment

  * Has history or presence of biliary obstruction or biliary disease, hepatic encephalopathy, advanced ascites, portal hypertension, esophageal /gastric variceal bleeding, hepatocellular carcinoma, previous liver transplantation.
  * Has severe or moderate renal dysfunction
  * Known to be human immunodeficiency virus (HIV) positive
  * Has clinically significant history or presence of illness, malignancy or immunodeficiency
  * Has had a blood transfusion or donated / lost 450 mL of blood or more within 60 days of study drug administrations or donated plasma within 7 days prior to clinical check-in
  * Has history of alcoholism or drug/chemical/substance abuse within past 2 years
* Subjects with Normal Hepatic Function

  * Has severe or moderate renal dysfunction
  * Known to be human immunodeficiency virus (HIV) positive
  * Has clinically significant history or presence of illness, malignancy or immunodeficiency
  * Has had a blood transfusion or donated / lost 450 mL of blood or more within 60 days of study drug administrations or donated plasma within 7 days prior to clinical check-in
  * Has history of alcoholism or drug/chemical/substance abuse within past 2 years
```

## Arms

- **Moderate Hepatic Impairment** (EXPERIMENTAL) — Subjects with Moderate Hepatic Impairment
- **Normal Hepatic Function** (EXPERIMENTAL) — Subjects with Normal Hepatic Function

## Interventions

- **ASP1941** (DRUG) — oral

## Primary Outcomes

- **Pharmacokinetic variables used to assess the effect of hepatic function through analysis of blood samples** _(time frame: 7 days following study drug administration)_

## Secondary Outcomes

- **Pharmacokinetic variables used to assess the effect of hepatic impairment through analysis of blood and urine samples** _(time frame: 7 days following study drug administration)_

## Locations (1)

- Miami, Florida, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.|miami|florida|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01187186.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01187186*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*